You should hold the syringe at eye level to ensure you are reading the volume correctly at the bottom of the meniscus (the curve of the liquid)
The dissolved solution should be clear blue from the copper-bound GHK-Cu
AOD 9604 is a modified fragment of the human growth hormone molecule, specifically the amino acids 176 to 191 at its tail end
The Wells score is determined by major risk factors (recent history of surgery or bed rest, immobilization, or presence of cancer), physical exam findings (edema, engorgement, enlargement, tenderness, and superficial vein dilation in the affected limb), and history (previous DVT and absence of another likely explanation for signs and symptoms)
What to Expect in Months 7-11 Essentially no side effects: Appetite suppression continues (desired effect), but GI symptoms gone Weight loss velocity slows: From 0.8kg/week (months 3-6) to 0.3-0.5kg/week Plateau around week 40-48: Weight stabilizes, no longer losing despite continued medication Total weight loss: Average 20-24% from baseline (matching or exceeding surgical outcomes) Focus shifts to maintenance: Accepting current weight, preventing regain Plateau frustration: Not a side effect but an emotional challenge 2 Final Strategies for Months 7-11 20
Read more in our Thymosin Alpha-1 immune research guide